AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

Bristol Myers Squibb (NYSE:BMY) has tapped Cristian Massacesi, as executive vice president, chief medical officer, and head of development, effective August 1, 2025. Massacesi most recently served as ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

The company’s AI approach allows molecule candidates to be vetted for efficacy and other properties early in development.

Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. In ...

The companies' new effort would bypass traditional middlemen to cut the drug's monthly cost from a list price of around $606 ...

Bristol Myers Squibb has appointed Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development.

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth strategies offset patent expiries.

Bristol-Myers Squibb Company (NYSE: BMY) is one of the stocks Jim Cramer reflected on. When asked about the stock during the ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.